BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31769876)

  • 1. Impact of age at diagnosis of de novo metastatic prostate cancer on survival.
    Bernard B; Burnett C; Sweeney CJ; Rider JR; Sridhar SS
    Cancer; 2020 Mar; 126(5):986-993. PubMed ID: 31769876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
    Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
    Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
    Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
    Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
    Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
    Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
    Ritter MA
    Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
    Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
    Vatandoust S; Kichenadasse G; O'Callaghan M; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis CS; Moretti K
    BJU Int; 2018 May; 121 Suppl 3():48-54. PubMed ID: 29603585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?
    Wæhre H; Vlatkovic L; Cvancarova M; Paus E; Fosså SD; Danielsen HE
    Scand J Urol; 2014 Apr; 48(2):123-30. PubMed ID: 23885810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
    Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
    World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of Gleason scores in metastatic prostate cancer.
    Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
    Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era.
    Mendhiratta N; Lee T; Prabhu V; Llukani E; Lepor H
    Urology; 2015 Oct; 86(4):783-8. PubMed ID: 26163812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
    Jackson WC; Suresh K; Tumati V; Dess RT; Soni PD; Zhao SG; Zumsteg ZS; Hannan R; Hollenbeck BK; George A; Kaffenberger SD; Salami SS; Hearn JWD; Morgan TM; Mehra R; Schipper M; Feng FY; Desai NB; Spratt DE
    Eur Urol Oncol; 2018 Sep; 1(4):276-282. PubMed ID: 31100248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
    Kang JJ; Reiter RE; Steinberg ML; King CR
    Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.
    Lin DW; Porter M; Montgomery B
    Cancer; 2009 Jul; 115(13):2863-71. PubMed ID: 19466697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
    Seikkula HA; Kaipia AJ; Ryynänen H; Seppä K; Pitkäniemi JM; Malila NK; Boström PJ
    Int J Cancer; 2018 Mar; 142(5):891-898. PubMed ID: 29044563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.